Drugs / GSK3339036A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02547974 | Aug 2015 → Mar 2017 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3339036A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02547974 ↗ |
| Modality | Vaccine | “different investigational vaccine formulations containing surface proteins of NTHi (PD and PE-PilA) and Mcat (UspA2)” PMID 31029515 ↗ Apr 2019 |
| Route | Intramuscular | “Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule” NCT02547974 ↗ |